Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.
Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB; Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Oliveira GB, et al. Among authors: eisenstein el. Arch Intern Med. 2008 Jan 14;168(1):94-102. doi: 10.1001/archinternmed.2007.65. Arch Intern Med. 2008. PMID: 18195201
Outcomes of second revascularization procedures after stent implantation.
Konstance RP, Eisenstein EL, Anstrom KJ, Shaw LK, Califf RM, Harrington RA, Matchar DB, Schulman KA, Kong DF. Konstance RP, et al. Among authors: eisenstein el. J Med Syst. 2008 Apr;32(2):177-86. doi: 10.1007/s10916-007-9120-x. J Med Syst. 2008. PMID: 18461821
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ; ENDEAVOR III Investigators. Eisenstein EL, et al. JACC Cardiovasc Interv. 2009 Dec;2(12):1199-207. doi: 10.1016/j.jcin.2009.10.009. JACC Cardiovasc Interv. 2009. PMID: 20129546 Free article. Clinical Trial.
158 results